Fintel reports that on February 5, 2025, Jefferies upgraded their outlook for Cardinal Health (NYSE:CAH) from Hold to Buy.

Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.

Wells Fargo analyst Stephen Baxter maintained Cardinal Health with an Equal-Weight and raised the price target from $135 to ...

Shares of Cardinal Health Inc. CAH advanced 1.82% to $127.45 Wednesday, on what proved to be an all-around great trading ...

Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its ...

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardinal Health (CAH – Research Report) and Apyx ...

Drug distributor Cardinal Health said on Thursday it may need to increase prices of some of its products if the proposed tariffs on Mexico go into effect, to counter increasing costs of manufacturing ...

Jan 30 (Reuters) - Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its ...

Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher prices for some of the company's products will follow. Trump is set to ...

Dublin City Schools is officially withdrawing from an agreement with Cardinal Health to purchase a vacant office building, Superintendent John Marschhausen told board members at a meeting Monday ...

Robust demand across its pharmaceutical and specialty solutions segment was the impetus behind Cardinal Health raising its fiscal 2025 enterprise guidance, said Jason Hollar, CEO of Cardinal ...